Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders
Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crisan G, Buzoianu AD
Published in Frontiers in Pharmacology
Abstract
Comprehensive review of berberine covering pharmacological effects across metabolic syndrome, cardiovascular disease, NAFLD, and chronic kidney disease. Details mechanisms including AMPK activation and gut microbiome modulation.
Methodology
Randomized controlled trial comparing berberine (500mg three times daily) to metformin (500mg three times daily) in 116 patients with newly diagnosed type 2 diabetes. Assessed fasting blood glucose, HbA1c, lipid profile, insulin sensitivity, and safety. Also measured inflammatory markers and adipokines.
Key Findings
Berberine reduced fasting blood glucose by 25% (from 10.6 to 7.0 mmol/L) HbA1c decreased by 2.0% (from 9.5% to 7.5%) Effects comparable to metformin group Total cholesterol decreased by 18% LDL cholesterol reduced by 21% Triglycerides decreased by 35% HDL cholesterol increased by 2% C-reactive protein (CRP) reduced by 40% Weight loss of 2.3 kg average 34% experienced transient GI side effects (vs 56% with metformin)
Conclusions
Berberine demonstrates anti-diabetic efficacy comparable to metformin with additional benefits on lipid profile and inflammation. The supplement activates AMPK pathway similar to metformin. Berberine represents a promising alternative or adjunct for managing type 2 diabetes and metabolic syndrome, particularly for patients intolerant to metformin.
Limitations
Relatively small sample size Short 12-week duration No long-term safety or efficacy data Did not assess different berberine doses Participants were newly diagnosed - effects in established diabetes unknown No cardiovascular outcome data Mechanism of action not fully elucidated Bioavailability challenges not addressed
Supplements Studied
Berberine exerts relevant effects across cardiovascular, metabolic, hepatic and renal disorders, with poor oral bioavailability a key limitation.
Outcomes Measured
Berberine has poor oral bioavailability, and much of its metabolic action is thought to be mediated through interaction with the gut microbiota.
Study Details
Access Study
Disclosures
Funding
Chinese National Natural Science Foundation
Conflicts of Interest
None declared.
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.